GLP-1 Medications: Complete 2026 Comparison Guide (Wegovy, Ozempic, Zepbound, Mounjaro)
Medically Reviewed by
Board Certified Endocrinologist
Published
Mar 18, 2026
Last Reviewed
Mar 18, 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Which GLP-1 Medication Is Best? The Direct Answer
For maximum weight loss, tirzepatide (Zepbound, 15mg) leads all approved medications at 20.9% average body weight loss at 72 weeks. For cardiovascular benefit with the most data, semaglutide (Wegovy) has the SELECT trial proving a 20% reduction in major cardiovascular events. For type 2 diabetes with weight loss, both Ozempic and Mounjaro are strong options. For needle-free oral dosing, Rybelsus (semaglutide tablet) is the only option — with more modest weight loss. The best drug for you depends on your clinical goals, insurance, and tolerance.
Drug-by-Drug Breakdown
Wegovy (semaglutide 2.4mg/week): FDA-approved for weight management (2021) and cardiovascular risk reduction (2024). Average weight loss: 14.9% at 68 weeks (STEP 1). SELECT trial shows 20% MACE reduction. Monthly cost without insurance: ~$1,350. Best for: weight management with cardiovascular benefit, Medicare patients with established CVD. Ozempic (semaglutide 0.5–2.0mg/week): FDA-approved for type 2 diabetes and cardiovascular risk reduction. Average weight loss: 4–12% depending on dose and population. Monthly cost: ~$900–$1,080. Best for: patients with T2DM needing glycemic control plus weight loss. Zepbound (tirzepatide 2.5–15mg/week): FDA-approved for weight management (2023). Average weight loss: 20.9% at 72 weeks (SURMOUNT-1). Monthly cost: ~$1,060. Best for: maximum weight loss in non-diabetic patients. Mounjaro (tirzepatide 2.5–15mg/week): FDA-approved for type 2 diabetes. Same molecule as Zepbound. Monthly cost: ~$1,023. Best for: T2DM patients who want maximum weight loss alongside glycemic control. Saxenda (liraglutide 3.0mg/day): FDA-approved for weight management. Daily injection. Average weight loss: 5–8%. Monthly cost: ~$1,400. Best for: patients who didn't tolerate weekly injections or need flexible daily dosing. Rybelsus (semaglutide 3–14mg/day oral): FDA-approved for type 2 diabetes. Modest weight loss (~3–5% in T2DM). Monthly cost: ~$850. Best for: needle-averse patients with type 2 diabetes.
Head-to-Head Comparison: Key Metrics
Mechanism: Wegovy/Ozempic/Saxenda/Rybelsus are GLP-1 receptor agonists; Zepbound/Mounjaro are dual GLP-1+GIP receptor agonists. Dosing frequency: Wegovy/Ozempic/Zepbound/Mounjaro are once weekly; Saxenda and Rybelsus are daily. Route: all are subcutaneous injection except Rybelsus (oral tablet). Trial weight loss: Zepbound 20.9% > Wegovy 14.9% > Ozempic 4–12% > Saxenda 5–8% > Rybelsus 3–5%. Cardiovascular data: Wegovy (SELECT) and Ozempic (SUSTAIN-6) have established MACE reduction; Zepbound CVOT pending. Medicare coverage: Wegovy (for CVD patients); others only for T2DM indication. Compounding availability: semaglutide products have compounded alternatives; tirzepatide compounding is legally more restricted.
Cost Comparison: With and Without Insurance
Without insurance (retail list prices, 2026): Wegovy $1,350/month, Zepbound $1,060/month, Mounjaro $1,023/month, Ozempic $900–1,080/month, Saxenda $1,400/month, Rybelsus $850/month. With manufacturer savings cards (commercially insured patients who qualify): all Novo Nordisk and Lilly products can be as low as $25/month. With insurance prior authorization approved: typical copays $25–$100/month depending on plan. Medicare Part D: Wegovy covered for eligible patients with CVD; diabetes-indication drugs (Ozempic, Mounjaro) covered for T2DM patients. Compounded semaglutide: $149–$399/month via telehealth platforms. Compounded tirzepatide: legally more restricted; fewer legitimate options available.
How to Choose: A Clinical Decision Framework
If you have obesity without diabetes and want maximum weight loss: Zepbound (tirzepatide) at maximum dose is the evidence-based choice. If you have obesity and established cardiovascular disease: Wegovy has the SELECT trial proving cardiovascular benefit; Medicare may cover it. If you have type 2 diabetes and obesity: both Mounjaro and Ozempic are approved; Mounjaro typically produces more weight loss. If insurance covers only the diabetes indication: Ozempic or Mounjaro are the covered choices. If you can't afford branded medications: compounded semaglutide (not tirzepatide, due to legal restrictions) is the most accessible option. If you hate needles: Rybelsus is the only FDA-approved oral option, but weight loss is significantly more modest. If you tried one and it didn't work well: switching between drug classes or to the other dual-agonist is reasonable after 12–16 weeks at maximum tolerated dose.
Who Qualifies for GLP-1 Medications?
FDA labeling for Wegovy and Zepbound requires BMI ≥30 (obesity), or BMI ≥27 with at least one weight-related comorbidity. Qualifying comorbidities include: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, established cardiovascular disease, NAFLD/NASH, PCOS, and obesity-related osteoarthritis. Ozempic and Mounjaro require a type 2 diabetes diagnosis regardless of BMI. Insurance may add requirements beyond FDA thresholds: documentation of BMI, qualifying comorbidities, and prior weight loss attempts (behavioral program, diet, or other medications). For Medicare patients: Wegovy is now covered for patients with established cardiovascular disease and obesity.
Side Effects: What to Expect From Each Drug
All GLP-1 and GLP-1/GIP medications share a similar GI side effect profile. Common across all: nausea (most frequent, especially during dose escalation), vomiting, diarrhea, constipation, abdominal pain, and decreased appetite. Drug-specific differences: tirzepatide (Zepbound/Mounjaro) tends to cause more sulfur burps and bloating due to GIP receptor activation; semaglutide products may cause slightly higher rates of nausea and constipation. Saxenda (daily liraglutide) has more injection-site reactions due to daily dosing. Most GI side effects resolve or significantly improve after 8–12 weeks as the body adapts. Rare but serious: pancreatitis (all GLP-1 drugs carry a warning), gallstones (modest increased risk), and potential thyroid C-cell concerns (boxed warning based on rodent studies; not established in humans).
GLP-1 Drug Price Comparison
Updated March 2026 · Prices shown are average monthly retail costs. Actual costs vary by pharmacy and insurance plan.
| Drug | Indication | Admin | Without Insurance | With Insurance | Avg. Weight Loss | |
|---|---|---|---|---|---|---|
WegovyMost Popular Novo Nordisk | Weight Loss | Weekly Injection | $1,349/mo | $25–$200/mo | ~15–20% | Check Price |
Ozempic Novo Nordisk | Type 2 Diabetes | Weekly Injection | $935/mo | $25–$150/mo | ~12–15% | Check Price |
ZepboundBest Results Eli Lilly | Weight Loss | Weekly Injection | $1,059/mo | $25–$175/mo | ~20–22% | Check Price |
Mounjaro Eli Lilly | Type 2 Diabetes | Weekly Injection | $1,069/mo | $25–$150/mo | ~18–20% | Check Price |
RybelsusNeedle-Free Novo Nordisk | Type 2 Diabetes | Daily Pill | $850/mo | $10–$100/mo | ~5–8% | Check Price |
Without insurance
$1,349/mo
With insurance
$25–$200/mo
Avg. weight loss
~15–20%
Administration
Weekly Injection
Without insurance
$935/mo
With insurance
$25–$150/mo
Avg. weight loss
~12–15%
Administration
Weekly Injection
Without insurance
$1,059/mo
With insurance
$25–$175/mo
Avg. weight loss
~20–22%
Administration
Weekly Injection
Without insurance
$1,069/mo
With insurance
$25–$150/mo
Avg. weight loss
~18–20%
Administration
Weekly Injection
Without insurance
$850/mo
With insurance
$10–$100/mo
Avg. weight loss
~5–8%
Administration
Daily Pill
* Prices are estimates based on average pharmacy retail pricing. Always verify with your pharmacy or insurance. Some links are affiliate links — we may earn a commission at no extra cost to you.
Frequently Asked Questions
These answers are for informational purposes only. Always consult your physician for personalized medical advice.
Was this article helpful?
Scientific References & Further Reading
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022.
- FDA Drug Approvals Database — GLP-1 Receptor Agonists. U.S. Food & Drug Administration.
- PubMed — GLP-1 Receptor Agonist Research Index. National Library of Medicine.
- Mayo Clinic — GLP-1 Agonists for Type 2 Diabetes and Obesity. Mayo Clinic Proceedings.
This content is produced in accordance with GLP-1 Health's editorial standards and is based on peer-reviewed clinical evidence from the sources cited above. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.
